Lantern Pharma Inc
For the period ended Dec 31, 2023. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 18, 2024
LTRN$0.46-22.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets – December 31, 2023 and 2022
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| CURRENT ASSETS | ||
| Cash and cash equivalents | $21,937,749 | $37,201,786 |
| Restricted cash | - | 541,180 |
| Marketable securities | 19,364,923 | 17,994,299 |
| Prepaid expenses & other current assets | 2,038,653 | 2,985,472 |
| Total current assets | 43,341,325 | 58,722,737 |
| Property and equipment, net | 52,127 | 48,008 |
| Operating lease right-of-use assets | 228,295 | 47,687 |
| Other assets | 25,869 | 17,889 |
| TOTAL ASSETS | $43,647,616 | $58,836,321 |
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $2,505,211 | $2,745,407 |
| Operating lease liabilities, current | 172,975 | 52,890 |
| Total current liabilities | 2,678,186 | 2,798,297 |
| Operating lease liabilities, net of current portion | 61,496 | - |
| TOTAL LIABILITIES | 2,739,682 | 2,798,297 |
| COMMITMENTS AND CONTINGENCIES (NOTE 4) | - | - |
| STOCKHOLDERS’ EQUITY | ||
| Preferred Stock (1,000,000 authorized at December 31, 2023 and December 31, 2022; $.0001 par value) (Zero shares issued and outstanding at December 31, 2023 and December 31, 2022) | - | - |
| Common Stock (25,000,000 authorized at December 31, 2023 and December 31, 2022; $.0001 par value) (10,721,192 shares issued and outstanding at December 31, 2023; 10,857,040 shares issued and outstanding at December 31, 2022) | 1,072 | 1,086 |
| Additional paid-in capital | 96,258,726 | 95,691,194 |
| Accumulated other comprehensive loss | (107,460) | (371,386) |
| Accumulated deficit | (55,244,404) | (39,282,870) |
| Total stockholders’ equity | 40,907,934 | 56,038,024 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $43,647,616 | $58,836,321 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.